Press Releases Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
4.530 ^USD	-3.62%		-2.79%	-5.82%

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT

Press Releases

Mar. 03	Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna	GL
Nov. 14	Arbutus Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
Nov. 13	Arbutus: Q3 Earnings Snapshot	AQ
Nov. 13	Arbutus Biopharma : Corporate Presentation Nov 2025 FINAL	PU
Nov. 13	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update	GL
25-10-07	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025	GL
25-08-06	Arbutus: Q2 Earnings Snapshot	AQ
25-08-06	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update	GL
25-06-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus	GL
25-05-14	Arbutus: Q1 Earnings Snapshot	AQ
25-05-14	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update	GL
25-05-08	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver Congress 2025	AQ
25-05-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025	GL
25-05-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025	AQ
25-04-23	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025	GL
25-04-23	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025	AQ
25-03-27	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update	GL
25-03-03	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	GL
25-03-03	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	AQ
25-02-25	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO	AQ
25-02-25	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO	GL
25-01-13	Arbutus Biopharma : Corporate Presentation - January 2025	PU
25-01-13	Arbutus Provides 2025 Corporate and Financial Update	GL
24-12-03	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors	BU
24-11-26	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat	AQ